Scott Ely
About Scott Ely
Scott Ely is the Senior Scientific Director of Translational Medicine at Bristol Myers Squibb in Princeton, New Jersey, and serves as Hematopathology Associate Fellowship Director at Weill Cornell Medical College.
Title: Senior Scientific Director, Translational Medicine, Bristol Myers Squibb
Scott Ely is the Senior Scientific Director of Translational Medicine at Bristol Myers Squibb, located in Princeton, New Jersey. In this role, he is actively involved in leading the Translational Pathology Team within Translational Medicine. His primary responsibilities include biomarker strategy, development, and implementation for a range of diseases, including heme cancers, solid tumors, immunological conditions, and cardiovascular diseases. Ely also serves as a feasibility expert, troubleshooting and de-risking programs by leveraging his extensive key opinion leader (KOL) and site experience.
Professional Experience at Weill Cornell Medicine
Scott Ely served as an Associate Professor at Weill Cornell Medicine from 2010 to 2012. He is currently affiliated with Weill Cornell Medical College in the capacity of Hematopathology Associate Fellowship Director. Additionally, Ely worked at the Weill Medical College of Cornell University/New York Presbyterian Hospital, holding the position of M.D. Associate Professor during his tenure. Through these roles, Ely has significantly contributed to academic and clinical advancements in hematopathology and related fields.
Educational Background
Scott Ely holds an extensive educational background anchored in medicine and public health. He completed his Doctor of Medicine (MD) at Tulane University School of Medicine from 1987 to 1991. Concurrently, he attained a Master of Public Health (MPH) in Epidemiology and Nutrition from Tulane University School of Public Health and Tropical Medicine within the same period. Ely further pursued specialization in Hematology at the Joan & Sanford I. Weill Medical College of Cornell University, earning the title of Fellow, American Board of Pathology, from 1996 to 2020.
Developments in Diagnostic Biomarkers
Scott Ely has played a pivotal role in the development and implementation of diagnostic biomarkers for clinical trials, notably including those for Palbociclib. His contributions encompass the invention and patenting of diagnostic biomarkers utilized for clinical trial enrollment. Ely’s lab is recognized for providing multiplex-IHC data reports within 72 hours of specimen receipt during his academic tenure. Such innovations have substantially impacted the efficiency and accuracy of diagnostic procedures in clinical settings.
Global Contributions and Initiatives
In the global arena, Scott Ely has been instrumental in running NIH AIDS-cancer trials in Africa during his post-graduate years. At Bristol Myers Squibb, he is an active participant in the Opdivo (Nivolumab) heme Development Team and Multiple Myeloma Patient Advocacy efforts on a global scale. Ely is also a member of the Measurable Residual Disease (MRD) Task Force and contributes to the Personalized Medicine Coalition, specifically in the Pharma Preanalytics Working Group. His global outreach underscores his commitment to advancing medical research and patient care worldwide.